Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

European Journal of Cancer

Volumn 40, Issue 5, 2004, Pages 689-695

  Debiec Rychter, M ^a   Dumez, H ^a   Judson, I ^b   Wasag, B ^a   Verweij, J ^c   Brown, M ^d   Dimitrijevic, S ^e   Sciot, R ^a   Stul, M ^a   Vranck, H ^a   Scurr, M ^b   Hagemeijer, A ^a   Van Glabbeke, M ^d   Van Oosterom, A T ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

c KIT; Gastrointestinal stromal tumours; Imatinib mesylate; PDGFRA

Indexed keywords

IMATINIB; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TYROSINE KINASE RECEPTOR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENATURATION; DISEASE COURSE; DNA SEQUENCE; DRUG RESPONSE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT FOR CANCER; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SCREENING; SOFT TISSUE SARCOMA; SURVIVAL; SURVIVAL RATE; TISSUE REACTION;

ADULT; AGED; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 12144291080     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.025     Document Type: Article

References (19)

1. Antonescu C.R., Sommer G., Sarran L.et al. Association of KIT Exon 9 mutations with nongastric primary site and aggressive behaviour. KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors Clin. Cancer Res. 9:2003;3329-3337.
2. Chan P.M., Ilangumaran S., La Rose J., Chakrabartty A., Rottapel R. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol. Cell Biology. 23:2003;306-3078.
3. Chen H., Isozaki K., Kinoshita K.et al. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int. J. Cancer. 105:2003;130-135.
4. Demetri G.D., von Mehren M., Blanke C.D.et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. New Eng. J. Med. 347:2002;472-480.
5. Fletcher J.A., Corless C.L., Dimitrijevic S.et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumot (GIST). Proc. Am. Soc. Clin. Oncol. 2003;405. (abstr 3275).
6. Frost M.J., Ferrao P.T., Hughes T.P., Hughes T.P., Ashman L.K. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Therapeutics. 1:2002;1115-1124.
7. Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity. a novel molecular approach to the treatment of KIT-positive malignancies J. Clin. Oncol. 20:2002;1692-1703.
8. Heinrich M.C., Corless C.L., Blanke C.et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc. Am. Soc. Clin. Oncol. 2002;405. (abstr 6).
9. Heinrich M.C., Corless C.L., Von Mehren M.et al. PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST). Proc. Am. Soc. Clin. Oncol. 2003;405. (abstr 3274).
10. Heinrich M.C., Corless C.L., Duensing A.et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710.
11. Hirota S., Isozaki K., Moriyama Y.et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
12. Lasota J., Wozniak A., Sarlomo-Rikala M.et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. a study of 200 cases Am. J. Pathol. 157:2000;1091-1095.
13. Rubin B.P., Singer S., Tsao C.et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121.
14. Singer S., Rubin B.P., Lux M.L.et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncology. 20:2002;3898-3905.
15. Tuveson D.A., Willis N.A., Jacks T.et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein. biological and clinical implications Oncogene. 20:2001;5054-5058.
16. Wardelmann E., Neidt I., Bierhoff E.et al. C-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod. Pathol. 15:2002;125-136.
17. Van Oosterom A.T., Judson I.R., Verweij J.et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal tumors. a phase I study Lancet. 358:2001;1421-1423.
18. Van Oosterom A.T., Judson I.R., Verweij J.et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors. a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer. 5:2002;S83-S87.
19. Verweij J., van Oosterom A., Blay J.Y.et al. Imatinib mesylate 5STI-571 Glivec®, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer. 39:2003;2006-2011.